Compare VTS & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | EIKN |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.0M | 631.0M |
| IPO Year | 2022 | 2026 |
| Metric | VTS | EIKN |
|---|---|---|
| Price | $18.76 | $8.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $20.00 | ★ $25.60 |
| AVG Volume (30 Days) | 437.7K | ★ 466.8K |
| Earning Date | 05-04-2026 | 03-30-2026 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $273,989,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $15.00 | $7.90 |
| 52 Week High | $24.92 | $16.50 |
| Indicator | VTS | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 78.39 | 40.11 |
| Support Level | $17.33 | $8.43 |
| Resistance Level | $20.13 | $10.20 |
| Average True Range (ATR) | 0.40 | 0.88 |
| MACD | 0.11 | -0.19 |
| Stochastic Oscillator | 92.86 | 0.41 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.